Enhanced Anticancer Effect of Cholesteryl Doxorubicin Liposome-Extracellular Vesicle Hybrid for Cancer Gene Therapy

Strategic Insights -

Researchers from Yeungnam University, South Korea, have made significant progress in the field of cancer gene therapy by developing a novel hybrid delivery system combining extracellular vesicles (EVs) with cholesteryl-doxorubicin liposomes. This innovative approach leverages the advantages of both EVs and liposomes to enhance cellular uptake, facilitate endosomal escape, and improve the delivery of anticancer agents.

Key Takeaways:

  • The hybrid EVs were formulated by fusing EVs isolated from adipose-derived stem cells (ADSCs) with cholesteryl-Dox liposomes using the freeze-thawing method, achieving an encapsulation efficiency of 91.6 ± 1.4%.
  • The hybrid EVs exhibited enhanced cytotoxicity and inhibited tumor growth more effectively than liposomal formulation or free Dox in animal experiments, without causing significant body weight loss.
  • The successful formation of hybrid EVs was validated by confirming the retention of key EV membrane markers and observing changes in the fluorescence spectrum via FRET assay, indicating membrane fusion.
  • This study highlights the potential of hybrid EVs as a promising drug delivery platform for cancer therapy, combining the advantages of both liposomes and EVs.
  • The research was financially supported by the Engineering Research Center Program and the National Research Foundation of Korea.
  • Additional authors for this research include Jong-Soo Choi and Jae-Won Park.

Statistics:

  • 91.6% ± 1.4% encapsulation efficiency of doxorubicin in hybrid EVs
  • Enhanced cytotoxicity of hybrid EVs compared to liposomal formulation or free Dox
  • Inhibition of tumor growth by 75% using hybrid EVs in animal experiments
  • Good biocompatibility of hybrid EVs with minimal body weight loss effect

Sources:

  • Enhanced Anticancer Effect of Cholesteryl Doxorubicin Liposome-extracellular Vesicle Hybrid. Journal of Drug Delivery Science and Technology, 2025;109
  • NewsRx. New Findings from Yeungnam University in the Area of Cancer Gene Therapy Described (Enhanced Anticancer Effect of Cholesteryl Doxorubicin Liposome-extracellular Vesicle Hybrid). Cancer Weekly. July 8, 2025; p 47